Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Janssen Cilag International
Sponsor

Janssen Cilag International

Belgium Turnhoutseweg 30, 2340 Beerse, Belgium

About the sponsor

Multiple myeloma, relapsed or refractory myeloma, chronic lymphocytic leukemia, small lymphocytic lymphoma, non-Hodgkin lymphoma, acute myeloid leukemia, myelodysplastic neoplasms, and AL amyloidosis are prominent areas of interest, alongside studies in mantle cell lymphoma and other B-cell malignancies.

  • Multiple myeloma and plasma cell disorders
  • B-cell non-Hodgkin lymphoma and CLL/SLL
  • Acute leukemia and myelodysplastic neoplasms

Research also extends to warm autoimmune hemolytic anemia and other haematology-focused conditions.

About Specializations

Janssen Cilag International runs clinical trials in conditions such as Plasma cell myeloma, Colitis ulcerative, Non-small cell lung cancer, Crohn's disease, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

137 clinical trials

Study of JNJ-78934804 (guselkumab and golimumab) versus guselkumab in adults with moderately to severely active Crohn’s disease

Recruiting
InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

Major depression

Recruiting
Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:SELTOREXANT
  • Sponsor:Janssen Cilag International

Plasma cell myeloma refractory

Recruiting
Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tocilizumab
  • Sponsor:Janssen Cilag International

Colitis ulcerative

Recruiting
InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

Non-small cell lung cancer

Recruiting
InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen Cilag International

Plasma cell myeloma refractory

Recruiting
InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Teclistamab
  • Sponsor:Janssen Cilag International

Crohn's disease

Recruiting
Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Systemic lupus erythematosus

Recruiting
Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Nipocalimab
  • Sponsor:Janssen Cilag International

Plasma cell myeloma refractory

Recruiting
InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Teclistamab
  • Sponsor:Janssen Cilag International

Hormone-refractory prostate cancer

Recruiting
Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Janssen Cilag International

Myasthenia gravis

Recruiting
Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Janssen Cilag International

Crohn's disease

Recruiting
Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:ICOTROKINRA
  • Sponsor:Janssen Cilag International

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.